Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine
A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 200 participants.
Also called NCT05850091
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 200 participants
- Registry
-
NCT05850091
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05850091. Randomized; quadruple masking; primary purpose treatment. Start 2023-12-07 (actual); primary completion 2027-06-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine
- Acronym
- PROACT 2
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Rosuvastatin
- Intervention (Drug)
- Colchicine
- Intervention (Drug)
- Placebo
- Lead sponsor
- Massachusetts General Hospital
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
Record details
- Record id
cardio:ct-nct05850091- Content hash
db7e6ddc0abbf49809cc119bf56820500928b2cce4f0733bcfdaf54930b1c93c